Medicines labeled for the same conditions
Alternatives to tirzepatide
14 other medicines are given the same way (subcutaneous) and in the same FDA class as tirzepatide or labeled mainly for the same use (type 2 diabetes); 6 are in its class, glucose-dependent insulinotropic polypeptide receptor agonists: liraglutide, semaglutide, dulaglutide, exenatide and 2 more; the others include 6 insulin analogs, 1 insulin and 1 amylin analog (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $31.41 per mL (Liraglutide 2-pak 18 mg/3 mL) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as tirzepatide?
Type 2 diabetes lists all 52 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Tirzepatideglucose-dependent insulinotropic polypeptide receptor agonist | this medicine | none listed | $538.68 per mL 10 mg/0.5 mL pen | Yes | No current entry |
| LiraglutideGLP-1 receptor agonist · same class | Heart attack and coronary artery disease, Type 2 diabetes, Weight management | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | Yes | In shortage |
| SemaglutideGLP-1 receptor agonist · same class | Heart attack and coronary artery disease, Type 2 diabetes, Weight management | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | Yes | A presentation being discontinued |
| DulaglutideGLP-1 receptor agonist · same class | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $487.57 per mL 0.75 mg/0.5 mL pen | Yes | No current entry |
| ExenatideGLP-1 receptor agonist · same class | Type 2 diabetes | 1 labeler | $300.17 per mL 10 mcg dose pen injection | No | No current entry |
| Insulin degludec and liraglutideGLP-1 receptor agonist · same class | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | Yes | No current entry |
| Insulin glargine and lixisenatideGLP-1 receptor agonist · same class | Type 2 diabetes | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No | No current entry |
| Insulin glargineinsulin analog | Type 2 diabetes | none listed | $2.90 per mL 100 pen | No | A presentation being discontinued |
| Insulin aspartinsulin analog | Type 2 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No | No current entry |
| Insulin lisproinsulin analog | Type 2 diabetes | none listed | $10.19 per mL 100 unit/mL kwikpen | No | A presentation being discontinued |
| Insulin humaninsulin | Type 2 diabetes | none listed | $4.26 per mL 70-30 vial | No | No current entry |
| Insulin degludecinsulin analog | Type 2 diabetes | none listed | $11.39 per mL 100 unit/mL pen | No | No current entry |
| Pramlintideamylin analog | Type 2 diabetes | none listed | n/a | Yes | A presentation being discontinued |
| Insulin detemirinsulin analog | Type 2 diabetes | none listed | n/a | No | No current entry |
| Insulin glulisineinsulin analog | Type 2 diabetes | none listed | $8.16 per mL 100 unit/mL vial | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Tirzepatide: the full record
- label, generics, price, shortages, recalls
- Tirzepatide vs liraglutide
- two records side by side
- Semaglutide vs tirzepatide
- two records side by side
- Dulaglutide vs tirzepatide
- two records side by side